Evidence to date: talazoparib in the treatment of breast cancer

Approximately 5-10% of all patients diagnosed with breast cancer have germline mutations, which make their disease more susceptible to DNA-damaging agents and a new class of drugs known as poly(ADP-ribose) polymerase (PARP) inhibitors. Talazoparib is a new PARP inhibitor that has been recently appro...

Full description

Saved in:
Bibliographic Details
Published inOncoTargets and therapy Vol. 12; pp. 5177 - 5187
Main Authors Exman, Pedro, Barroso-Sousa, Romualdo, Tolaney, Sara M
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.07.2019
Dove
Dove Medical Press
Subjects
Biotechnology
BRCA mutation
BRCA mutations
Breast cancer
Cancer metastasis
Cancer patients
Cancer treatment
Carboplatin
Care and treatment
Chemotherapy
Clinical trials
Comparative analysis
Development and progression
Disease susceptibility
DNA
Genetic aspects
homologous recombination deficiency
Monosaccharides
Niraparib
Olaparib
Pharmaceutical industry
Review
Risk factors
Rucaparib
Talazoparib
United States
breast cancer
talazoparib
homologous recombination deficiency
BRCA mutation
Online AccessGet full text

Cover

More Information
Summary:Approximately 5-10% of all patients diagnosed with breast cancer have germline mutations, which make their disease more susceptible to DNA-damaging agents and a new class of drugs known as poly(ADP-ribose) polymerase (PARP) inhibitors. Talazoparib is a new PARP inhibitor that has been recently approved for use in patients with metastatic breast cancer with germline mutations after a phase III trial showed superior progression-free survival when compared to standard chemotherapy. In this review, we analyze the development of talazoparib as well as its safety profile and the potential role of the combination therapy with standard cytotoxic drugs and with novel therapies.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S184971